PSY61 Who told you that: Do guidelines for including patient-centered outcome measures in systemic lupus erythematosus clinical trials include patient input?  by Curry, C. & Greene, A.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A121 
 
 
PSY56  
EXPANDING CONCEPTS OF OPIOID-TAKING BEHAVIOR IN SICKLE CELL 
DISEASE: A MULTI-PHASE, MIXED METHODS STUDY  
Alsalman AJ, Li Wong JK, Hassan NT, Smith WR 
Virginia Commonwealth University, Richmond, VA, USA  
OBJECTIVES: The rapid growth in opioid therapy for non-cancer pain has 
occurred without an adequate appreciation of the consequences of this growth. 
Few studies provide patient-centered evidence that can be used to inform the 
current proposed standards for efficacious (safe and effective) opioid prescribing 
in non-cancer pain. Furthermore, different terms may be used interchangeably 
in the literature to refer to opioid-taking behaviors, resulting in imprecise or 
vague interpretation of existing evidence. We therefore sought to explore 
patterns of opioid-taking behavior and their biopsychosocial-spiritual 
determinants in African-American adults with sickle cell disease (SCD). 
METHODS: We conducted a multi-phase mixed methods study which included 
quantitative and semi-structured qualitative interviews. A grounded theory 
approach was used to analyze the data. RESULTS: The final sample consisted of 
11 men and 10 women, average age 36 years. Qualitative thematic analysis 
uncovered several patterns of opioid-taking behavior and several related 
biopsychosocial- spiritual phenomena, some hypothesized and some not. These 
patterns and phenomena portrayed a new six-domain conceptual framework 
that addresses the complex individual, relational, environmental, cultural, and 
system issues surrounding opioid taking-behavior in SCD, and provides a 
roadmap for future research: 1) Pain and its consequences; 2) Prescribed opioid-
taking behaviors and their biopsychosocial consequences; 3) Effects of 
biopsychosocial determinants on opioid-taking behaviors; 4) Aberrant behavior; 
5) Physician prescribing behaviors and attitudes; and 6) Hypothetical targets for 
interventions to improve prescribing and opioid taking-behaviors. Further, the 
data portrayed explanatory factors that could be classified into various levels or 
domains based on models proposed in prior research. Factors included within-
patient (biological, spiritual, psychological), and social and environmental (social 
support, provider relationships, institutional norms, culture, legal and 
governmental policy) domains. CONCLUSIONS: The explored domains offer rich 
guidance toward understanding multi-level explanatory effect of pain, its 
pharmacotherapy, and medication taking behaviors on SCD individual’s health 
that simultaneously bridges all health care domains.  
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BIOPSYCHOSOCIAL-SPIRITUAL DETERMINANTS OF OPIOID-TAKING  
BEHAVIOR IN SICKLE CELL DISEASE: A MULTI-PHASE, MIXED METHODS  
STUDY  
Alsalman AJ, Li Wong JK, Hassan NT, Smith WR 
Virginia Commonwealth University, Richmond, VA, USA  
OBJECTIVES: Many questions surround opioid use for non-cancer pain, but little 
has been published about behavioral patterns of taking opioids in these conditions. 
The objective of this abstract is to report partial results: patterns of opioid use, and 
effects of biopsychosocial-spiritual determinants on opioid-taking behaviors. 
METHODS: As part of a multiphase, mixed-method study, we conducted wide-
ranging quantitative and semi-structured, qualitative interviews of African-
American adults with sickle cell disease (SCD). The final sample consisted of 11 
men and 10 women, average age 36 years, from various socioeconomic and 
educational levels. We used a grounded theory approach to analyze the data. 
RESULTS: Qualitative thematic analysis revealed three phenomena 1) SCD patients 
exhibited various opioid-taking behavior patterns including adherence, overuse, 
underuse, and erratic use; 2) A wide variety of biopsychosocial-spiritual factors 
hindered or motivated opioid use: pain intensity; side effects; fear of addiction; 
perceived stigma or judgment by others; senses of responsibility, productivity, 
hopelessness, or obligation; stress; social role pressure; social desirability; bullying; 
and anticipatory fear of adverse outcomes; and 3) Behaviors varied based on the 
time of day, week, month, or year, and based on context at times of doses. 
CONCLUSIONS: In summary, we found that contextual factors may drastically 
affect opioid-taking behaviors. Together, These uncovered phenomena raise new 
hypotheses that may challenge current theories and models of medication-taking 
behaviors and methods of assessing adherence. These hypotheses call for a new 
round of research on opioid-taking behavior, and need to be rigorously tested in 
future research.  
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A CONJOINT ANALYSIS TO EVALUATE ATTRIBUTE CHOICES AND FEATURE 
TRADE-OFFS IN OTC ANALGESIC PRODUCT PURCHASE  
Sahu A1, Nayak R2 
1St. Johns University, New York, NY, USA, 2St. John's University, Jamaica, NY, USA  
OBJECTIVES: To utilize Conjoint Analysis to evaluate the relative importance of 
extrinsic and intrinsic product attributes in OTC analgesic purchase and 
examine feature trade-offs in product choice. METHODS: A cross-sectional 
questionnaire survey with profile cards and convenience sample. Consumers 
shopping at three New York City pharmacies and two convenience stores were 
recruited and asked to rank order profile cards based on their preference for 
different combinations of product features. Conjoint analysis employing 
fractional factorial design with an orthogonal array was used to generate 11 
profile cards each for a pair of product attributes (extrinsic and intrinsic). 
Attributes were analyzed separately and combined, along with multiple levels 
within each attribute. All feature configurations: price, brand image & promotion 
(extrinsic); and effectiveness, side effects & dose regimen (intrinsic); were 
assigned average importance scores and Part-Worth utility scores for all levels 
within. Importance of each profile relative to other profiles within and across the 
two attributes was determined. RESULTS: The pilot phase of the study (n=32) 
showed significant Kendall’s Tau correlation among profile cards (0.873), 
confirming instrument validity. In the main study sample (n=103), with respect 
to extrinsic attributes, Part-Worth Utility scores indicated price as being the most 
preferred attribute (1.456) compared to brand image (-1.469) and promotion 
(0.013). With respect to intrinsic attributes, dose regimen was preferred (1.097) 
over effectiveness (-0.257), followed by side effects (-0.838). The percentage 
preference analysis indicated a greater influence of extrinsic features on 
consumer product choice compared to intrinsic features (57.36% vs. 42.64%). 
CONCLUSIONS: Overall, in decisions regarding choice of a right analgesic 
product, extrinsic attributes matter more to the consumer than intrinsic 
features. Brand image and promotional aspects are traded off in favor of price, 
and dosing convenience is strongly preferred over side effects profile and 
product effectiveness.  
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WEB-BASED STUDY OF PATIENTS AND CAREGIVERS IN THE UNITED STATES 
AND CANADA: PERSPECTIVES ON IMPROVEMENTS IN STABILITY OF FACTOR 
VIII PRODUCTS FOR HEMOPHILIA A  
DiBenedetti DB1, Coles TM1, Ling C2, Sharma T3, Pericleous L3 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK, 
3Novo Nordisk A/S, Søborg, Denmark  
OBJECTIVES: Hemophilia A is a rare, inherited bleeding disorder in which the 
affected individual lacks or has limited production of coagulation factor VIII 
(FVIII), resulting in the inability of the blood to clot normally. Treatment typically 
involves life-long replacement of FVIII through intravenous infusions to stop or 
prevent spontaneous or traumatic bleeds. However, FVIII storage and stability 
remain a constant challenge. Obtaining patients’ and caregivers’ perspectives is 
critical to disease management, particularly with rare conditions. A web-based 
survey was developed to assess hemophilia A patients’ and caregivers’ 
preferences around FVIII storage and stability attributes. METHODS: Individuals 
with hemophilia A and caregivers of minor children with hemophilia A from 
local and national hemophilia support groups in the United States and Canada 
were invited to complete a web-based survey assessing patients’ FVIII ordering, 
usage, and storage routines. RESULTS: Of the 145 individuals who responded to 
the survey invitation, 101 individuals (67% caregivers [82% female]) completed 
the survey (70%). Nearly half (48%) of respondents ordered FVIII monthly, and 8% 
reported often having FVIII vials expire before their use. Challenges to storing 
FVIII included refrigeration when traveling (28%) and carrying an insulated tote 
bag (27%). More than half (54%) preferred a new FVIII product with longer storage 
at room temperature. The majority (80%) indicated preference for a FVIII product 
that could be stored at a higher room temperature for longer durations, primarily 
for ease in traveling, keeping more factor at home, and having easy access when 
needed. CONCLUSIONS: This web-based study provides a unique perspective 
from patients and caregivers on treatment attributes that are important to this 
population. There is a need for an improved FVIII product that offers more 
convenience and faster access to patients in daily life and while traveling. 
Additionally, flexibility in storage potentially could reduce the frequency of FVIII 
wastage.  
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CHANGES IN PAIN INTENSITY AND HEALTHRELATED QUALITY OF LIFE 
(HRQOL) IN PATIENTS WITH PERIPHERAL NEUROPATHIC PAIN AFTER 
TREATMENT WITH 8% CAPSAICIN PATCH – RESULTS FROM A NORDIC 
PROSPECTIVE OBSERVATIONAL STUDY  
Persson CA1, Hansson P2, Jensen TS3, Kvarstein G4, Magnusson K1 
1Astellas Pharma A/S, Kastrup, Denmark, 2Karolinska University Hospital, Stockholm, Sweden, 
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OBJECTIVES: To examine the effect of 8% capsaicin patch on change in “usual 
pain” using a modified PNRS (Pain Numeric Rating Scale). A secondary objective 
was to examine utility scores assessed by the EQ-5D-3L. METHODS: Adult 
patients diagnosed with peripheral neuropathic pain (excluding diabetic 
polyneuropathy) were included. Each patient was eligible to receive up to two 
treatments. Parameters: PNRS, patient’s pain intensity over the past 24 hours: 
usual, highest, lowest and right now EQ-5D-3L Size of treated area RESULTS: A 
total of 412 patients were included, 382 patients completed first treatment 
period, 266 with partial peripheral nerve injury; 51 with post herpetic neuralgia 
(PHN); 19 with polyneuropathy and 46 with other painful neuropathies. Fifty-
nine percent were women, mean age was 53 years (range 18–88). A total of 184 
patients were given a re-treatment and 181 patients completed the re-treatment 
period. PNRS: Usual pain intensity over the past 24 hours (maximum pain 
reduction at any time point) decreased from 6.3 to 4.4 (p < 0.001) and at re-
treatment from 6.3 to 5.0 (p < 0.001). Mean EQ-5D health score was 0.33 (SD 0.32) 
at baseline (range -0.38-1.00). During the post-treatment period the mean change 
was 0.25 (SD 0.29), (p < 0.001). At baseline, 58% of all patients reported “Extreme 
Problem” in the pain/discomfort dimension and corresponding figures for the 
post-treatment period was 38%. Mean EQ-5D health score was 0.54 (SD 0.32) at 
start of re-treatment (range -0.26-1.00). During the post-re-treatment period the 
mean change was 0.17 (SD 0.28 (p < 0.001). The area treated had at baseline a 
median size of 180 cm2 and at re-treatment 160 cm2. CONCLUSIONS: In this 
population of patients with peripheral neuropathic pain and a markedly reduced 
QoL, treatment of capsaicin 8% significantly reduced patients’ experience of 
“usual pain” and improved short-term HRQoL evaluated by EQ-5D-3L.  
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OBJECTIVES: The importance of patient-centered outcomes (PCO) in drug 
development is increasingly recognized by health authorities, clinical advisory 
and patient advocacy bodies. Accordingly, many of these organizations seek to 
include PCO in their guidelines and recommendations. However, complex 
disorders present measurement challenges that are difficult to resolve within the 
scope of a clinical trial (CT). An example is Systemic Lupus Erythematosus (SLE), 
characterized by myriad clinical indicator, symptom, severity and frequency 
combinations. SLE patient burden studies demonstrate that, while symptoms 
differ, the impact is universal. This study evaluates the relationship between 
recently updated SLE guidances and concepts reported directly by SLE patients. 
METHODS: A qualitative study comprised of six SLE patient focus groups (N=43) 
was conducted to elicit direct patient input on key symptoms and concepts. FDA 
and EMA guidelines for SLE clinical trials, European League Against Rheumatism 
(EULAR) CT endpoint recommendations, and the Systemic Lupus International 
Collaborating Clinics (SLICC) classification system were evaluated for PCO-
specific content. Patient-reported outcomes (PRO) concepts from the study were 
then compared to the PCO content from the guidelines and recommendations. 
RESULTS: All study subjects (mean age 44.3 years; 91.7% women; 63% diagnosed 
≥ 5 years; 91% experienced flare ≤ 3 months; 74% mild/moderate disease) 
identified fatigue among “most important symptoms” with 98% citing pain and 
44% fog/confusion. Regardless of “importance” all subjects deemed other 
symptoms highly disruptive. EMA and FDA both specify fatigue as a clinical trial 
endpoint. FDA included “fatigue” based on clinician input, but recommended 
development of a PRO-based fatigue exploratory endpoint. EULAR, citing 
challenges of symptom endpoints, suggested general Health-Related Quality of 
Life. The SLICC didn’t mention PCOs. CONCLUSIONS: Patients identified multiple 
SLE symptoms and impacts, yet guidances didn’t address these issues. Joint 
efforts between patients, sponsors, regulators and advisory organizations are 
necessary to implement relevant PCOs, especially in complex disorders.  
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COMPARISON OF CLINICAL AND COST CHARACTERISTICS AMONG PATIENTS 
WITH INFLAMMATORY BOWEL DISEASE ACROSS DIFFERENT SITES OF CARE  
Vanderpoel J1, Schenkel B1, Lofland J1, DiBonaventura M2, Gross H3 
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Kantar Health, New York, NY, USA,  
3Kantar Health, Princeton, NJ, USA  
OBJECTIVES: To compare clinical and cost characteristics among patients with 
inflammatory bowel disease (IBD) receiving biologic medication in an in-office 
setting (IOI), hospital outpatient department (HOPD), or ambulatory clinic. 
METHODS: A syndicated study of IBD patients was conducted. Patients aged ≥18 
years were recruited via the National Health and Wellness Survey and 
Lightspeed Research Panel to complete a survey during August–November 2010. 
Patients were asked about health care utilization, concomitant medications, IBD 
symptoms, quality of life (QoL) and out-of-pocket (OOP) costs. To measure 
utilization, the number of provider, emergency room (ER), and hospital visits in 
the past 6 months was collected. The Medical Outcomes Study (MOS) IBD 
questionnaire was used to assess QoL. Bivariate differences were assessed using 
Fisher’s exact tests for categorical variables and ANOVAs for continuous 
variables. RESULTS: Of 175 IBD patients, 54% (n=94) received biologic medication 
in an IOI setting, 35% (n=61) in an HOPD setting, and 11% (n=20) in an ambulatory 
clinic. The number of ER and hospital visits were similar across groups, however 
IOI patients had greater provider visits (p<0.05). Though concomitant medication 
utilization was generally similar, significantly more IOI patients received steroids 
compared to HOPD patients (p<0.05). Most IBD symptoms did not differ across 
groups. However, HOPD patients were more likely to have fistulas than IOI 
patients (30% vs. 16%; p<0.05), and IOI patients were less likely to experience 
bowel movements than HOPD or clinic patients (55% vs. 84% and 80%, 
respectively). HOPD patients had lower OOP costs for biologic medications and 
higher QoL scores compared to IOI patients (p<0.05). CONCLUSIONS: Among IBD 
patients receiving biologic medication in an IOI, HOPD, or ambulatory clinic 
setting, HOPD patients had higher QoL and lower OOP costs, however, few other 
differences were identified. Further research is needed to elucidate these 
findings.  
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CORRELATES OF IMPROVEMENT IN PHYSICAL QUALITY OF LIFE AND QUALITY 
OF SLEEP AMONG CHRONIC LOW BACK PAIN PATIENTS WITH TREATMENT 
WITH BUPRENORPHINE TRANSDERMAL SYSTEM (BTDS)  
Miller K1, Yarlas A1, Wen W2, Kowalski M2, Lynch SY2, Dain B2, Ripa SR2 
1Optum, Lincoln, RI, USA, 2Purdue Pharma L.P., Stamford, CT, USA  
OBJECTIVES: Deficits in physical health-related quality of life (HRQL) and sleep 
quality in chronic low back pain (CLBP) patients may be alleviated with 
Buprenorphine Transdermal System (BTDS) treatment. This post-hoc analysis of 
clinical trial data aimed to explore whether BTDS treatment has a direct impact 
on HRQL and sleep quality, an indirect impact on the outcomes as mediated 
through its impact of pain, or both; and to identify significant correlates of HRQL 
and sleep quality. METHODS: In this multicenter, enriched, double-blind, 
randomized trial, opioid-naïve patients with moderate-to-severe CLBP received 
twelve weeks’ treatment with BTDS (10 or 20 mcg/hour) or placebo. A series of 
multivariate linear regression models (stepwise) predicting physical HRQL, sleep 
disturbance, and sleep quality at week 12 were fitted. Physical HRQL was 
measured using the SF-36v2 Physical Component Summary (PCS), while sleep 
outcomes were measured using the Disturbance subscale and Sleep Problems 
Index (SPI) of the Medical Outcomes Study Sleep Scale (MOS-SS). For each 
outcome, models 1 and 2 included baseline demographic and clinical variables, 
model 3 added treatment arm, and model 4 added pain assessment at week 8. 
RESULTS: Results from model 3 supported BTDS treatment as a significant 
predictor of better physical HRQL and sleep outcomes. Model 4 results for each 
outcome indicated that pain was a partial mediator of treatment on physical 
HRQL and sleep quality, meaning that treatment had both direct and indirect 
effects on these outcomes. Mid-trial pain and the baseline value of the outcome 
being tested (i.e., PCS score, Disturbance score, or SPI score) were the strongest 
predictors for each outcome. CONCLUSIONS: For CLBP patients, improvements 
in physical HRQL, sleep disturbance, and sleep quality were impacted by BTDS 
treatment both directly as well as indirectly via mediation through the 
treatment-driven reductions in pain. Mid-trial pain strongly predicted to HRQL 
and sleep outcomes.  
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RESPONSIVENESS AMONG PATIENT-REPORTED MEASURES OF QUALITY OF 
LIFE, QUALITY OF SLEEP, AND FUNCTIONAL DISABILITY TO PAIN AND IMPACT 
OF BUPRENORPHINE TRANSDERMAL SYSTEM (BTDS) TREATMENT IN CHRONIC 
LOW BACK PAIN PATIENTS  
Yarlas A1, Miller K1, Wen W2, Shah R2, Lynch SY2, Dain B2, Ripa SR2 
1Optum, Lincoln, RI, USA, 2Purdue Pharma L.P., Stamford, CT, USA  
OBJECTIVES: Patients with moderate-to-severe chronic low back pain (CLBP) who 
are treated with Buprenorphine Transdermal System (BTDS) experience 
improvements in three patient-reported outcomes: quality of life (QoL), sleep 
quality, and functioning. This analysis compared the relative responsiveness of 
measures of each outcome to treatment and treatment-driven changes in pain. 
METHODS: This post-hoc analysis used data from an enriched, 12-week double-
blind, randomized placebo-controlled trial evaluating BTDS (10 or 20 mcg/hour) 
for treatment of pain in opioid-naive patients with moderate-to-severe CLBP. 
The trial repeatedly assessed QoL (SF-36v2), sleep quality and problems (Medical 
Outcomes Study Sleep Scale [MOS-SS]), and functional disability (Oswestry 
Disability Index [ODI]) in addition to measures of pain. Responsiveness of each 
instrument to treatment and changes in pain were examined using analysis of 
covariance, t-tests, and effect sizes for comparison of effects of time, treatment, 
and magnitude of pain reduction. The interrelation among PROs was also 
examined. RESULTS: The SF-36v2 and ODI showed better responsiveness to 
treatment and changes in pain than did the MOS-SS. Among subscales of the 
MOS-SS, only Disturbance showed substantial correlations with other PRO and 
pain measures and substantial differences across time, treatment, and pain 
reduction status groups. Several of the QoL domains measured by the SF-36v2, 
particularly Bodily Pain, Physical Functioning, Role Physical, Social Functioning, 
and Vitality, showed considerable responsiveness to treatment and pain. For the 
ODI, the Pain Intensity subscale showed the greatest responsiveness, with the 
majority of the remaining subscales showing more moderate, but still 
meaningful, levels of responsiveness. PRO measures were, in general, 
moderately inter-correlated, particularly between SF-36v2 and ODI subscales. 
CONCLUSIONS: Pain subscales on the SF-36v2 and ODI showed the greatest 
responsiveness to treatment. Substantial responsiveness was also observed for 
the majority of QoL and functioning domains, as well as sleep disturbance. 
Subscales of PRO instruments were generally moderately inter-correlated.  
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CONTENT VALIDITY OF A NEW OBESITY-SPECIFIC HEALTH RELATED QUALITY 
OF LIFE (HRQOL) INSTRUMENT – FABQOL  
Wang VW1, Aw FWL1, Ma T2, Wong MTK2, Wee HL1 
1National University of Singapore, Singapore, Singapore, 2Khoo Teck Puat Hospital, Singapore, 
Singapore  
OBJECTIVES: Obesity has become a major public health problem worldwide. In 
Singapore, the prevalence of obesity among adults aged 18-69 years increased 
from 6.9% in 2004 to 10.8% in 2010. To the best of our knowledge, no single 
obesity-specific HRQoL instrument comprehensively covered areas of life that 
are important to obese individuals. Therefore we sought to assess the content 
validity of FABQOL, a newly developed instrument, to address the gap. 
METHODS: FABQOL (76 items) was developed based on literature review and 
mapped to obesity-specific International Classification of Functions Disability 
and Health (ICF) categories. Content validity (i.e. item comprehension and 
content coverage) was assessed through individual cognitive debriefing 
interviews with 30 English-speaking, ethnic Chinese, Malay and Indian 
overweight/obese patients from a weight management clinic at a public hospital 
in Singapore. For each item, we asked participants if the item was important to 
them (yes/no). Items that were perceived as not important by at least 50% of the 
participants and items that were not understood by at least 20% of the 
participants were removed. Participants were also asked to suggest additional 
items that were important. RESULTS: Participants aged from 23-58 years (median 
age = 45), one-third were men and 90% were obese (BMI>27.5kg/m2). Two items 
“being able to eat as much as I want to” and “being able to reach for objects 
placed above me” were perceived as not important by 26 (87%) and 15 (50%) of 
participants respectively. Four items (“lethargic”, “distressed”, “anxious” and 
“stigmatized”) were removed because they were poorly understood. Three 
participants suggested three new items pertaining to relationship with close 
friends, company image and personal leisure activities. CONCLUSIONS: The 
revised FABQOL comprises 73 items that were generally easy to understand and 
important to overweight/obese patients in Singapore. Psychometric properties of 
FABQOL will be evaluated in a larger study.  
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